The 15% Number: What the Scale Actually Showed
The headline result from the semaglutide trial is the magnitude of weight loss. Here is what was actually measured, in plain English.
The first and most-cited result from the STEP 5 trial is the magnitude of weight loss. Participants on semaglutide lost roughly 15% of body weight over 68 weeks, versus about 2.4% on placebo. This article breaks that one result out so you can see exactly what was measured and what it does and does not tell you.
Why pull this one result out on its own? Because the magnitude finding is the load-bearing claim of the whole semaglutide weight-management story. If semaglutide did everything else but did not move the scale meaningfully, the story would be a footnote. The fact that it moved the scale by this much, in this population, over this window, is what makes the rest of the research worth doing. This is the result to understand first, and to understand honestly.
One line we will hold throughout, because popular coverage blurs it: an outcome result in a controlled trial is a population result. It tells you the average moved in the studied direction. It does not, by itself, tell you what your individual result would be, or what sustained use does over the longer arc past the window. We will keep that line visible here, because it is the line that gets erased in the sales version of this story.
What the scale actually showed
StudyThe researchers tracked body weight as percentage change from the starting weight, in 1,961 adults with overweight or obesity, over 68 weeks. The semaglutide group lost roughly 15% of body weight on average. The placebo group, which received the same lifestyle counseling, lost about 2.4%.
Both numbers matter, and the difference between them matters most. The placebo group moved a little — lifestyle counseling alone produced a small, real weight loss, which is what lifestyle counseling does. The semaglutide group moved substantially more. The gap between the two, not either number on its own, is the result. That gap is what tells you the signal is doing something on top of behavior.
It is also worth being precise about what '15% weight loss' means as a measurement. It is a percentage of starting body weight, averaged across the group, at the end of the 68-week window. It is not a claim that every participant lost 15%, that the loss was linear, or that the loss was sustained past the window. The average is the headline. The shape under the average — who lost more, who lost less, when the loss happened — is what the other sub-articles cover.
Why the magnitude matters
StudyMost behavioral weight-loss interventions — diet, exercise, counseling — produce roughly 5 to 8% weight loss over a year. 15% in this trial is in a different category, not a marginal improvement. That is why a single study moved semaglutide from one option among many to the center of the weight-management research conversation.
If you are researching weight management, you have probably seen a lot of small-percentage results. Supplements that move the scale 1 or 2%. Diets that produce 5% if you stick to them. A 15% result, sustained across a 68-week window in a population of nearly 2,000 adults, is not in that category. It is the kind of magnitude that changes how a field thinks about a problem.
The honest framing matters here, because the magnitude is exactly where the overclaiming happens. A large population result is not a promise of a large individual result. Some participants lost more than 15%. Some lost less. Some discontinued. The average is real and the average is large, and the average is not your individual number. Hold those apart, because the sales version of this story treats the average as a promise.
What this result does and does not tell you
StudyIt tells you the signal moves the scale, substantially, in the population studied, over the window measured. That is a real outcome result, and it is more than most of the literature in this library can hand you. It is the foundation of the case for semaglutide as a weight-management research topic.
It does not, by itself, tell you what sustained use does over the longer arc, what happens after the window ends, or what your individual result would be. Those are different questions with a different standard of evidence, and the literature is still working on them.
Read this result as the foundation, not the building. The foundation says the signal works in this population at this magnitude. Everything else — sustained use, individual application, what happens past the window — is the building, and it is the part the field is still constructing. Do not let anyone hand you the foundation and call it the building. That is the single most common move in the bad version of this story, and it is the move to watch for in every semaglutide writeup you read from here on.
More from this research
Talk it through with a specialist
Private, written, no commitment. A research specialist replies on your timeline.
This article is provided for educational purposes only and does not constitute medical advice. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. For research use only.